4//SEC Filing
Urist Marshall 4
Accession 0001838139-25-000008
CIK 0001802768other
Filed
Dec 8, 7:00 PM ET
Accepted
Dec 9, 5:00 PM ET
Size
8.1 KB
Accession
0001838139-25-000008
Insider Transaction Report
Form 4
Urist Marshall
EVP, Research & Investments
Transactions
- Sale
Class A Ordinary Shares
2025-12-05$39.15/sh−23,334$913,591→ 160,000 total(indirect: By LLC) - Sale
Class A Ordinary Shares
2025-12-05$39.15/sh−18,242$714,224→ 7,398 total
Holdings
- 19,020(indirect: By IRA)
Class A Ordinary Shares
Footnotes (2)
- [F1]All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 29, 2025.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.32 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Royalty Pharma plc
CIK 0001802768
Entity typeother
Related Parties
1- filerCIK 0001838139
Filing Metadata
- Form type
- 4
- Filed
- Dec 8, 7:00 PM ET
- Accepted
- Dec 9, 5:00 PM ET
- Size
- 8.1 KB